Surgical and systematic adjuvant treatment of head and neck primary melanoma;Operative und adjuvante medikamentose therapie des kutanen melanoms im Kopf-Hals-Bereich

Laryngo- Rhino- Otologie

Volumn 79, Issue 7, 2000, Pages 428-433

  Hauschild, A ^a   Lischner, St ^a   Christophers, E ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Adjuvant treatment; Interferons; Melanoma; Sentinel node; Surgery

Indexed keywords

ALPHA INTERFERON; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DACARBAZINE; INTERFERON;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; HEAD AND NECK CANCER; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; ADJUVANT CHEMOTHERAPY; CELL CULTURE; CLINICAL TRIAL; COMPARATIVE STUDY; HEAD AND NECK TUMOR; LYMPHADENECTOMY; MULTIMODALITY CANCER THERAPY; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DACARBAZINE; HEAD AND NECK NEOPLASMS; HUMANS; INTERFERONS; LYMPH NODE EXCISION; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033869963     PISSN: 09358943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-4632     Document Type: Article

References (30)

1. An analysis of prognostic factors in 8500 patients with cutaneous melanoma
2. Epidemiology of malignant melanoma in central Europe: Risk factors and prognostic predictors
3. Schleimhautmelanome der oberen Luft- und Speisewege
4. Das maligne Melanom der Kopf- und Halsregion
5. Therapie des malignen Melanoms: Derzeitiger Stand und Perspektiven
6. Operative Therapie kutaner Melanome
7. Malignant melanoma excision margins: Making a choice
8. Head and neck melanoma
9. Stellungnahme und Empfehlungen der Kommission Malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des Malignen Melanoms der Haut - Stand 1993/94
10. Narrow excision (1 cm margin): A safe procedure for thin cutaneous melanoma
11. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
12. Inefficacy of immediate node dissection in stage I melanoma of the limbs
13. Sentinel lymph-node biopsy in melanoma: Is less surgery better?
14. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy. An alternative to routine elective lymphadenectomy or 'watch and wait'
15. Technical details of intraoperative lymphatic mapping for early stage melanoma
16. Intraoperative lymphatic mapping and selective cervical lymphadenectomy for early-stage melanomas of the head and the neck
17. Intraoperative lymphatic mapping for early-stage melanoma of the head and neck
18. The use of lymphoscintigraphy in melanoma of the had and neck
19. Szintillationssondengesteuerte Sentinel-Lymphadenektomie beim malignen Melanom
20. Intraoperative radiolymphoscintigraphy improves sentinel lymph node identification for patients with melanoma
21. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma
22. Detection of melanoma micrometastasis in sentinel node by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastasis disease in the lymph node basin
23. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
24. Adjuvante Therapie des malignen Melanoms
25. The role of adjuvant therapy in melanoma management
26. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
27. Randomised trial of interferon alpha-2b as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
28. Adjuvant interferon-A2a treatment in resected primary stage II cutaneous melanoma
29. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
30. Vaccination of melanoma patients with peptide- or tumor lysate pulsed dendritic cells